Winners ECNP Poster Awards 1999
Winners ECNP Poster Awards at the 12th ECNP Congress 1999 - London, United Kingdom:
Poster session P.1 Affective disorders and antidepressants
Poster session P.2 Psychotic disorders and antipsychotics
Poster session P.3 Anxiety disorders and anxiolytics
Poster session P.4 Degenerative and neurological disorders
Poster session P.5 Addiction
Poster session P.6 Other topics
Please note that the winners are mentioned in alphabetical order of the first author.
Poster session P.1 Affective disorders and antidepressants
P.1.058
Altered 5-HT2A binding sites and inositol triphosphate levels in hippocampus from depressed suicide victims
Arranz, B., Rosel, P., Cano, R., Ramirez, N., Duenas, R., Navarro, M.A., San, L., Menni, B. - Spain
P.1.087
Thyroid axis activity and serotonin function in major depressive episode
Duval, F., Mokrani, M.C., Bailey, P., Diep, T.S., Crocq, M.A., Macher, J.P. - France
P.1.124
Selective adenosine A2a receptor antagonists are potential antidepressants: evidence based on the activity of SCH 58261 and A2a knockout mice in screening procedures
El Yacoubi, M., Ledent, C., Parmentier, M., Costentin, J., Vaugeois, J.-M. - France
P.1.085
Fluvoxamine in combination with pindolol hastens the response of delusional depressives
Franchini, L., Zanardi, R., Gasperini, M., Smeraldi, E., Perez, J. - Italy
P.1.072
The lithium side effects rating scale (LISERS); development of a self-rating instrument
Haddad, P., Wieck, A., Yarrow, M., Denham, P. - United Kingdom
P.1.106
Rapid remission of atypical depressive symptoms with the selective oradrenalin reuptake inhibitor reboxetine in SAD patients
Hilger, E., Willeit, M., Praschak-Rieder, N., Neumeister, A., Stastny, J., Thierry, N., Kasper, S. - Austria
P.1.003
Plasma noradrenaline and prediction of outcome in depressive illness
Kelly, C., Johnston, T., Stevenson, M., Cooper, S.J. - United Kingdom
P.1.067
Opioid involvement in antidepresant-type effect of NK3 receptor agonist, senktide, in the mouse forced swimming test
Kowalczyk, M., Panocka, I., Sadowski, B., Lapo, I., Masi, M. - Poland
P.1.036
PET neuroimaging shows antidepressant binding primarily at serotonin uptake sites in the dorsomedial thalamus of higher "animals"
Smith, D.F., Gee, A.D., Danielsen, E., Ishizu, K., Sakoh, M., Scheel-Krüger, J., Gjedde, A. - Denmark
P.1.093
Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans
Vollenweider, F.X., Liechti, M.E., Gamma, A., Geyer, M.A., Hell, D., Switzerland
Poster session P.2 Psychotic disorders and antipsychotics
P.2.056
Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with haloperidol
Boin, F., Maes, M., Bocchio Chiavetto, L., Bignotti, S., Tura, G.B., Boin, F., Racagni, G., van West, D., Kenis, G., Bosmans, E., Altamura, A.C. - Italy
P.2.126
Amygdala or ventral hippocampus lesions on day 7 of life in rat: an animal model of psychiatric neurodevelopmental disorders like schizophrenia
Daenen, E.W.P.M., Wolterink, G., Gerrits, M.A.F.M., Kruse, C.G., van der Heijden, J.A.M., van Ree, J.M. - The Netherlands
P.2.018
Tc-99 HMPAO SPECT study of regional cerebral blood flow in drug-free and olanzapine-treated schizophrenic patients
Gönül, A.S., Sofuoglu, S., Tutus, A., Kula, M., Bastürk, M., Esel, E., Aslan, S.S. - Turkey
P.2.125
Schizophrenic psychopathology and presynaptic dopamine synthetic activity: a positron emission tomography study with [18F] fluorodopa
Gründer, G., Davids, E., Heydari, N., Vernaleken, I., Benz, P., Schlösser, R., Andreas, J., Stoeter, P., Wong, D.F., Gjedde, A. - Germany
P.2.095
Is neuropeptide Y involved in the pathogenesis of disorders associated with hyperactivity of dopaminergic system?
Kask, A., Harro, J. - Estonia
P.2.050
Is there an association of response to haloperidol treatment with polymorphisms in the DRD2 or in the DRD3 receptor genes?
Schäfer, M., Rujescu, D., Guntermann, A., Giegling, I., Dittert, S., Möller, H.-J., Bondy, B. - Germany
Poster session P.3 Anxiety disorders and anxiolytics
P.3.012
Influence of the serotonin antagonist, metergoline, on anxiogenic and neuroendocrine effects of carbon dioxide in healthy volunteers
Ben-Zion, I.Z., Meiri, G., Greenberg, B.D., Murphy, D.L., Benjamin, J. - Israel
P.3.032
The role of 5-HT2 receptors in experimentally induced anxiety
Connell, J., Deakin, J.F.W. - United Kingdom
P.3.028
The mini-SPIN: a brief screening assessment for social phobia
Connor, K.M., Kobak, K., Churchill, L.E., Potts, N.L.S., Katzelnick, D., Davidson, J. - U.S.A.
P.3.037
Organotypic rat cerebellar slice culture as a model to analyze the molecular pharmacology of GABAa receptors
Davids, E., Hevers, W., Dämgen, K., Lüddens, H. - Germany
P.3.018
SSRIs revert the inhibitory effect of PKC on the 5-HT transporter in OCD
Marazziti, D., Masala, I., Baroni, S., Rossi, A., Presta, S., Giannaccini, G., Dell'Osso, L., Lucacchini, A., Cassano, G.B. - Italy
P.3.030
Spatial working memory in Obsessive Compulsive Disorder: a three-dimensial functional magnetic resonance imaging study
van der Wee, N., Ramsey, N., Jansma, J., van Megen, H., Westenberg, H., Kahn, R. - The Netherlands
Poster session P.4 Degenerative and neurological disorders
P.4.016
Treatment with selegiline in Alzheimer disease - SPECT evaluations
Gheorghe, M.D., Grigorescu, G. - Romania
P.4.005
Using a combined randomized start/withdrawal design to assess propentofylline's effects on disease progression in Alzheimer's disease and vascular dementia: results of clinical studies
Kittner, B. - U.S.A.
P.4.028
Donepezil preserves functional status in Alzheimer's disease patients: results from a 1-year prospective placebo-controlled attrition study
Mohs, R., Doody, R., Morris, J., Ieni, J.R., Rogers, S.L., Perdomo, C.A., Pratt, R.D.- U.S.A.
P.4.007
Nociceptin/orphanin FQ modulates spatial learning via ORL1-receptors in rats
Ögren, S.-O., Sandin, J., Terenius, L. - Sweden
Poster session P.5 Addiction
P.5.018
Buprenorphine versus methadone maintenance for the treatment of opioid dependence
Eder, H., Fischer, G., Gombas, W., Jagsch, R., Peternell, A., Stühlinger, G., Aschauer, H.N., Kasper, S. - Austria
P.5.016
Impaired cognitive performance in drug-free recreational ecstasy (MDMA) users raises concern about neurotoxic brain damage
Gouzoulis-Mayfrank, E., Daumann, J., Tuchtenhagen, F., Fimm, B., Sass, H. - Germany
P.5.014
Effectiveness of gabapentin on the substance-oriented behaviors of alcohol-dependent detoxified outpatients
Janiri, L., Hadjichristos, A., Pozzi, G., Costantino, D., Pecora, R., de Risio, S. - Italy
P.5.024
Acute psychological effects of 3,4-Methylenedioxymethamphetamine (MDMA, 'Ecstasy') are attenuated by the serotonin uptake inhibitor citalopram
Liechti, M.E., Baumann, Ch., Hell, D., Vollenweider, F.X. - Switzerland
Poster session P.6 Other topics
P.6.032
Preliminary, open-label study of topiramate in rapid cycling bipolar women
Kusumakar, V., Yatham, L., Kutcher, S., O'Donovan, C. - Canada
P.6.024
Changes in extracellular noradrenaline induced by conditioned environmental stimuli: a microdialysis study in the freely-moving rat
McQuade, R., Stanford, S.C. - United Kingdom
P.6.019
Inverse agonists and constitutive 5-HT1b receptor activation by a series of mutations in its BBXXB motif
Pauwels, P.J., Wurch, T. - France
P.6.053
Interleukin-6 activates STAT- and MAPK-signal transduction pathways and induces de novo-protein synthesis in human neuronal cells
Schumann, G., Huell, M., Machein, U., Hocke, G., Fiebich, B.L. - Germany
P.6.025
Towards a more rational use of psychoactive substances in clinical practice
Zitman, F.G., van Hyfte, D.M.H., de Vries Robbé, P.F., Tjandra-Maga, T.B., van der Maas, A.A. - The Netherlands
